The Centers for Disease Control and Prevention (CDC) is expanding its infectious disease surveillance program at four major U.S. airports as part of a new pilot program to provide early detection of more than 30 known pathogens, including influenza A and B, respiratory syncytial virus (RSV), and SARS-CoV-2.
The pilot is part of the agency’s Traveler-based Genomic Surveillance (TGS) program, implemented by biotech companies Ginkgo Bioworks and XpresCheck and will last several months.
